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ABSTRACT
Introduction: This analysis explored laboratory
mineral and bone disorder parameters and man-
agement of secondary hyperparathyroidism in
patients undergoing hemodialysis in Belgium,
Canada, China, France, Germany, Italy, Japan,
Russia, Saudi Arabia, Spain, Sweden, the UK, and
the USA.
Methods: Analyses used demographic, medica-
tion, and laboratory data collected in the
prospective Dialysis Outcomes and Practice Pat-
terns Study (2012–2015). The analysis included
20,612 patients in 543 facilities. Descriptive data
are presented as regional mean (standard devia-
tion), median (interquartile range), or prevalence,
weighted for facility sampling fraction. No testing
of statistical hypotheses was conducted.
Results: The frequency of serum intact parathy-
roid hormone levels[600 pg/mL was lowest in
Japan (1%) and highest in Russia (30%) and Saudi
Arabia (27%). The frequencyof serum phosphorus
levels[7.0 mg/dL was lowest in France (4%), the
UK (6%), and Spain (6%), and highest in China
(27%). The frequency of serum calcium levels
[10.0 mg/dL was highest in the UK (14%) and
China (13%) versus 2% to 9% elsewhere. Dialysate
calcium concentrations of 2.5 mEq/mL were
common in the USA (78%) and Canada (71%);
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concentrations of 3.0–3.5 mEq/L were almost
universal at facilities in Italy, France, and Saudi
Arabia (each C 99%).
Conclusions: Wide international variation in
mineral and bone disorder laboratory parameters
and management practices related to secondary
hyperparathyroidism suggests opportunities for
optimizing care.
Keywords: Bone mineral density; CKD; Dialysis;
ESRD; Hyperparathyroidism; Mineral metabo-
lism
Key Summary Points
Why carry out this study?
The prevalence of chronic kidney disease
(CKD) is increasing globally, which may
result in more patients receiving dialysis
despite current resource limitations.
Effective management is important
because of the morbidity and mortality
associated with secondary
hyperparathyroidism (SHPT) in patients
with CKD stage 5.
What was learned from the study?
This analysis explored laboratory mineral
and bone disorder parameters and
management of SHPT from multiple
dialysis facilities globally, and aimed to
identify differences in practices that
contribute to outcomes.
Wide international variation in mineral
and bone disorder laboratory parameters
and management practices related to
secondary hyperparathyroidism suggests
opportunities for optimizing care.
INTRODUCTION
The prevalence of chronic kidney disease (CKD),
including progression to CKD stage 5, is increas-
ing globally, including in the Middle East [1–4],
China [5], and Russia [6], presumably due to rising
prevalence of diabetes and hypertension [7–9].
More patients with CKD in resource-limited
countries are expected to receive dialysis in the
future, despite current gaps between need and
availability in lower-income countries [10]. Sec-
ondary hyperparathyroidism (SHPT) is a major
complication of CKD resulting from the failure of
one or more components of the calcium homeo-
static mechanism [11]. SHPT is an early compli-
cation ofCKD; serum intactparathyroidhormone
(iPTH) levels begin to rise when the glomerular
filtration rate (GFR) decreases to less than
approximately 60 mL/min/1.73 m2 (stage 3
CKD), although serum calcium and phosphorus
levels may be normal [12]. The estimated preva-
lence of SHPT, defined as iPTH[300 pg/mL, in
dialysis populations varies from approximately
30–50% across Europe, Asia, Oceania, and the
Americas [13].
A majority of patients with CKD stages 3–5
have CKD mineral and bone disorder (MBD) [14].
Parathyroid hormone is considered a uremic
toxin [15], and early diagnosis and treatment of
SHPT is essential because disorders of mineral
metabolism, i.e., hyperphosphatemia, hypercal-
cemia, SHPT, and elevated calcium–phosphorus
product (Ca 9 P), are associated with an increased
risk of mortality (all-cause and cardiovascular
[CV]-related) and hospitalization (all-cause, CV-
related, and fracture-related) in patients with end-
stage renal disease (ESRD) undergoing dialysis
[16, 17].
The Dialysis Outcomes and Practice Patterns
Study (DOPPS) is an international, prospective
cohort study of hemodialysis practice and patient
outcomes [18], with a main goal of identifying
practices that improve survival and quality of life
for patients undergoing hemodialysis [19]. In an
analysis of DOPPS phases 1–3 (1996–2007), which
included 25,882 patients [20], hyperphos-
phatemia (serum phosphorus[6.1–7.0 mg/dL),
hypercalcemia (serum calcium[10 mg/dL), and
elevated iPTH ([600 pg/mL) were identified as
three independent risk factors for all-cause and
CV mortality, with hazard ratios (HRs) of 1.18 and
1.61 for phosphorus 6.1–7.0 mg/dL, 1.43 and 1.81
for phosphorus[7.0 mg/dL, 1.16 and 1.24 for
calcium, and 1.21 and 1.17 for iPTH, respectively.
Moreover, it has been established that a Ca 9 P
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product[55 mg2/dL2 is associated with an
increased risk of cardiac calcification [21]. More
recently, using DOPPS phase 1–4 data
(1996–2011), an iPTH elevation to[600 pg/mL
(HR 1.23) and even milder elevation of iPTH
(301–450 pg/mL) were associated with mortality
compared with the reference range of
150–300 pg/mL (HR 1.09) [22]. Initial findings
from DOPPS phase 5 (2012–2015) in Russia and
countries of the Middle East that are part of the
Gulf Cooperation Council (GCC; Bahrain,
Kuwait, Oman, Qatar, Saudi Arabia, and United
Arab Emirates) have demonstrated variation in
practices and opportunities for improvement of
care [23, 24].
The objectives of this analysis are to identify
differences in practices that contribute to out-
comes across broad regions (Europe, Asia, the
Middle East, and North America) and, as a
result, to encourage regional collaboration as a
means to standardize treatment targets to
improve global outcomes.
METHODS
Study Design, Patients, and Data
Collection
The DOPPS international, prospective cohort
study of adult patients (C 18 years) undergoing in-
center hemodialysis randomly enrolled patients
from a sample of hemodialysis facilities within
each nation at the start of each study phase, as
described previously [18, 25]. The study was per-
formed in accordance with the Helsinki Declara-
tion of 1964 and its later amendments. The study
was approved by a central Institutional Review
Board in the USA (Ethical & Independent Review
Services). Outside of the USA, copies of IRB
approvals and/or exemptions were obtained for
each participating study site. Additional study
approval and patient consent were obtained as
required by national and local ethics committee
regulations.
The analysis described here includes data
collected in the initial prevalent cross-section of
patients enrolled in DOPPS phase 5 from 2012
to 2015 in 20,612 patients in 543 facilities
across Europe (Belgium, France, Germany, Italy,
Spain, Sweden, and the UK), Russia, Asia (China
and Japan), Saudi Arabia (results for additional
GCC countries have been published separately
[23]), and North America (Canada and the
USA). Specific parameters analyzed to assess the
management of SHPT included biochemical
measures and the use of SHPT medications.
Demographic data, comorbid conditions, labo-
ratory values, and medications were abstracted
from patient records.
Statistical Methods
All analyses were conducted using SAS software,
version 9.4 (SAS institute, Cary, NC). Descriptive
data are presented as regional mean (SD), med-
ian (interquartile range), or prevalence, weighted
for facility sampling fraction. No testing of sta-
tistical hypotheses was conducted.
RESULTS
Demographics
Median facility size varied across countries, rang-
ing from 52 patients per facility in the USA to 100
patients per facility in China. Other facility
characteristics were comparable among countries
(Table 1). Mean patient ages were noticeably
lower in Russia (52.7 years) and Saudi Arabia
(51.2 years) compared with other countries
(overall 63.0 years; range 58.6–69.7 years). The
median length of receiving dialysis was higher in
France (5.0 years) and Japan (6.4 years) compared
with other countries (overall 3.3 years; range
2.6–3.9 years). A majority of patients were men
(58%; range 54–64%). The mean body mass index
of patients in countries other than China
(21.8 kg/m2) and Japan (21.5 kg/m2) indicated
that they were overweight (overall 25.9 kg/m2;
range 25.0–28.4 kg/m2). Across all countries,
serum calcium and phosphorus were measured
for[90% of patients in the 4 months before
DOPPS enrollment (overall, 97% and 98%,
respectively; range 92–100%). However, serum
iPTH was collected less frequently in some coun-
tries, with at least 20% of patients not having a
measurement in the 4 months before DOPPS
Adv Ther
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enrollment in Russia (27%), the UK (24%), Saudi
Arabia (20%), and Japan (20%); iPTH data were
missing in 6–19% of patients in other countries.
Dialysate Calcium Values
Dialysate calcium concentrations varied among
countries, being lower in North America (the
USA and Canada) and the UK compared with
other countries, with 2.5 mEq/L predominantly
used (78%, 71%, and 59% of patients, respec-
tively) and\ 2.5 mEq/L also used in 17% of US
patients. Dialysate calcium concentrations of
3.0 mEq/L were especially common in Russia
(74%), Italy (95%), France (91%), and China,
Japan, and Saudi Arabia (67% for each), while
3.5 mEq/L was most frequently used in Saudi
Arabia (32%) and Russia (15%; Fig. 1).
Average Laboratory MBD Values
Mean values for total calcium were similar
across countries (range 8.7–9.2 mg/dL; Table 2).
The mean value for phosphorus was higher in
China (6.0 mg/dL) compared with other coun-
tries (range of mean values 4.4–5.4 mg/dL).
Mean iPTH values were higher in Russia
(571 pg/mL) and Saudi Arabia (540 pg/mL), yet
lower in Japan (150 pg/mL), compared with
other countries (range of mean values
262–439 pg/mL).
Categorical results for laboratory assessments
of serum analytes relevant to management of
patients with SHPT are shown in Fig. 2. Serum
iPTH levels[300 and[ 600 pg/mL were lowest
in Japan (10% and 1%), highest in Saudi Arabia
(58% and 27%) and Russia (57% and 30%), and
intermediate in other countries (range 31–54%
and 8–21%), while iPTH levels\ 150 pg/mL
were most commonly seen in Japan (62%) and
Germany (40%; Fig. 2a). Serum phosphorus
levels C 5.6 and[7.0 mg/dL were lowest in
several European countries and Canada (France
[22% and 4%], UK [30% and 6%], Spain [22%
and 6%], Belgium [22% and 7%], Italy [26% and
7%], and Canada [30% and 8%]), highest in
China (54% and 27%), and ranged from
33–44% and 10–14%, respectively, in other
countries (Fig. 2b). Serum calcium levels were
similar across countries, although there were
greater proportions of patients at the highest
levels (C 9.6 and[10.0 mg/dL) in the UK (33%
and 14%), China (27% and 13%), and Sweden
(27% and 9%), and at\ 8.4 mg/dL in Saudi
Arabia (31%; Fig. 2c).
The percentage of patients in each facility
who had at least one serum laboratory assess-
ment above a cutoff value is shown in Fig. 3.
The facility percentage of patients with serum
iPTH[600 pg/mL varied widely across coun-
tries, as well as within most countries, with
nearly all facilities in Japan having none of their
patients with such elevated iPTH values in
contrast to Russia, where 50% of the facilities
had at least 32% of their patients with
iPTH[600 pg/mL. For phosphorus, 50% of the
facilities in China had at least 48% of their
patients with values[6 mg/dL.
Medication Use for Mineral and Bone
Disorder Management
The use of vitamin D and vitamin D analogues
for managing MBD differed dramatically across
countries (Table 3). Cinacalcet was prescribed
most often in Saudi Arabia (29%), European
countries (range 13–34%), Japan (24%), and the
Fig. 1 Dialysate calcium values by DOPPS country
(2012–2015), weighted by facility sampling fraction and
sorted by proportion of patients in category of 2.5 mEq/L.
Bel Belgium, Can Canada, Chi China, DOPPS Dialysis
Outcomes and Practice Patterns Study, Eq equivalent, Fra
France, Ger Germany, Ita Italy, Jpn Japan, KSA Kingdom
of Saudi Arabia, pt patient, Rus Russia, Spa Spain, Swe
Sweden
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USA (18%), but infrequently prescribed in
China (1%), Russia (6%), and Canada (7%).
Most patients in the USA (65%) and Spain (57%)
but minorities in other countries (range 2–38%)
received vitamin D intravenously. Conversely,
use of oral vitamin D administration was low in
the USA (15%) and Spain (4%) compared with
other countries (range 21–73%). Most patients
received vitamin D by only one route; among
patients prescribed any vitamin D, the propor-
tions who received vitamin D both intra-
venously and orally were low across countries
(range 1–12%). Among types of vitamin D,
alfacalcidol monotherapy predominated in five
countries (the UK [96%], Sweden [92%], Saudi
Arabia [89%], Russia [85%], and France [82%])
but was used less elsewhere (range 0–62%).
Among patients prescribed vitamin D, calcitriol
monotherapy was common in China (79%) and
Canada (57%) but not in other countries (range
1–35%). Paricalcitol monotherapy use was
highest in Spain (87%), Italy (61%), and the
USA (45%) but low elsewhere (range 0–13%).
Use of other vitamin D types or combinations
was common only in Japan (39%) compared
with other countries (range 2–14%).
Phosphate binders were used less in China
(59%) compared with other countries (range
65–88%; Table 3). Among patients prescribed
phosphate binders, calcium-based monother-
apy was most prevalent in China (89%), Russia
(69%), Saudi Arabia (64%), and Canada (60%);
in other countries, minorities of patients
received this therapy (range 14–48%). Seve-
lamer monotherapy use was most frequent in
Italy (45%), the USA (37%), and Sweden (34%)
Fig. 2 Serum concentrations of MBD-related laboratory
assessments by DOPPS country (2012–2015), weighted by
facility sampling fraction and sorted by proportion of
patients in the highest category. a iPTH. b Phosphorus.
c Total calcium. Bel Belgium, Can Canada, Chi China,
DOPPS Dialysis Outcomes and Practice Patterns Study,
Fra France, Ger Germany, Ita Italy, Jpn Japan, KSA
Kingdom of Saudi Arabia, MBD mineral and bone
disorder, pt patient, iPTH intact parathyroid hormone,
Rus Russia, Spa Spain, Swe Sweden
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and least frequent in Russia (0%) and China
(1%); in other countries, 6–27% of patients
received sevelamer monotherapy. Less than
one-quarter of patients prescribed a phosphate
binder in each country received calcium-based
phosphate binder plus sevelamer dual treat-
ment (range 0–24%). Other binders or combi-
nations of phosphate binders were most
commonly used in Germany (45%), Spain
(42%), Japan (38%), and Russia (30%) and 6% to
28% in other countries.
Targets for Serum Laboratory Parameters
Target values for MBD laboratory assessments, as
reported by facility medical directors across
regions, are shown in Fig. 4. The lower and upper
targets for serum iPTH were usually 150 and
300 pg/mL, respectively; however, the most com-
mon lower and upper targets in Japan were 50
and B 200 pg/mL, respectively (Fig. 4a). Lower
targets for serum phosphorus were generally
between 2.5 and 3.5 mg/dL; upper targets usually
were 5.5 or 6.0 mg/dL (Fig. 4b). There was a broad
range between the most common lower and upper
targets in Russia (2.5 and 6.0 mg/dL, respectively).
Lower targets for serum calcium were commonly
8.0 or C 8.5 mg/dL, with C 8.5 mg/dL strongly
favored in Russia and Saudi Arabia; upper targets
were broadly distributed and usually centered at
10.0 mg/dL (but higher in North America at
10.5 mg/dL; Fig. 4c).
DISCUSSION
Optimizing the management of SHPT in patients
with CKD stage 5 receiving hemodialysis presents
an opportunity to decrease morbidity and mor-
tality. Published guidelines are inconsistent
regarding optimal target laboratory values,
resulting in lack of consensus on treatment tar-
gets [26–31]. Although clinical trial data are
lacking [32], iPTH concentrations[300–600 pg/
mL have been associated with increased risk of all-
cause and CV mortality, and all-cause and CV-
related hospitalizations in patients undergoing
hemodialysis [16, 20, 22, 33]. Elevated levels of
iPTH may also contribute to worsening hyper-
calcemia and hyperphosphatemia in patients
receiving hemodialysis [34]. Conversely, it is
expected that more effective control of iPTH
would not only enable good control of phosphate
and calcium levels but also translate to reduced
mortality and morbidity.
The ultimate goal of optimizing iPTH levels
is to improve bone health in this population.
Fig. 3 Distribution of the percentage of patients in each
facility who had a serum laboratory assessment higher than
the upper limit value by DOPPS country (2012–2015),
sorted by median proportion of patients. a iPTH[ 600 pg/
mL. b Phosphorus[ 6 mg/dL. Bel Belgium, Can Canada,
Chi China, DOPPS Dialysis Outcomes and Practice Patterns
Study, Fac facility, Fra France, Ger Germany, Ita Italy, Jpn
Japan, KSA Kingdom of Saudi Arabia, pt patient, iPTH
intact parathyroid hormone, Rus Russia, Spa Spain, Swe
Sweden. *Restricted to facilities with C 10 non-missing
values for the laboratory assessment of interest
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The assessments and treatment practices
observed in DOPPS phase 5 among countries
and regions have possible implications for
patient outcomes due to identification of best
practices. The iPTH targets in most countries are
consistent with the 2009 and 2017 Kidney Dis-
ease: Improving Global Outcomes (KDIGO)
guidelines, which both advocate a target of 2–9
times the upper limit of normal [14, 26], as well
as the National Kidney Foundation Kidney
Diseases Outcomes Quality Initiative (KDOQI)
clinical practice guidelines, which suggest a
target of 150–300 pg/mL [27]. However, Japa-
nese guidelines recommend a more stringent
Table 3 Medications by DOPPS country (2012–2015) as a percentage of patients
Europe Rus Asia and Middle
East
North
America
Bel Fra Ger Ita Spa Swe UK Chi Jpn KSA Can USA
Medications prescribed*
Cinacalcet 15 27 16 21 34 24 13 6 1 24 29 7 18
Phosphate binder 77 75 82 76 82 88 72 83 59 84 86 78 65
IV vitamin D 2 4 10 38 57 14 3 5 2 37 28 4 65
Oral vitamin D 32 21 46 26 4 70 73 48 57 41 51 61 15
Medications details
Vitamin D route
Oral only 94 83 81 37 5 84 96 91 96 50 60 94 16
IV only 5 16 15 57 94 13 2 7 1 46 28 5 81
IV ? oral 2 1 4 6 2 3 2 3 2 5 12 2 3
Vitamin D (IV or oral) type
Alfacalcidol only 62 82 51 0 3 92 96 85 17 38 89 41 0
Calcitriol only 29 4 30 35 4 1 1 2 79 24 7 57 10
Paricalcitol only 0 0 13 61 87 6 0 7 0 0 0 0 45
Other vitamin D or combination 10 14 5 4 6 2 4 7 4 39 4 2 3
Phosphate binder type
Calcium-based only 48 36 30 14 21 21 42 69 89 43 64 60 36
Sevelamer only 15 25 14 45 27 34 25 0 1 6 11 12 37
Calcium-based ? sevelamer only 24 22 11 14 10 21 8 2 0 13 19 15 13
Other binder or combination 13 18 45 28 42 24 25 30 10 38 6 13 14
Bel Belgium, Can Canada, Chi China, DOPPS Dialysis Outcomes and Practice Patterns Study, Fra France, Ger Germany,
Ita Italy, IV intravenous, Jpn Japan, KSA Kingdom of Saudi Arabia, Rus Russia, Spa Spain, Swe Sweden
*Prescription at DOPPS enrollment or in the month before DOPPS enrollment; vitamin D restricted to active vitamin D
(calcitriol or one of its synthetic analogues)
Restricted to patients prescribed the drug class of interest
Patient data are weighted for the facility sampling fraction
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Fig. 4 MBD lower and upper targets for serum concen-
trations of laboratory assessments, as reported by medical
directors by DOPPS country or region (2012–2015).
a iPTH, pg/mL. b Phosphorus, mg/dL. c Total calcium,
mg/dL. DOPPS Dialysis Outcomes and Practice Patterns
Study, MBD mineral and bone disease, iPTH intact
parathyroid hormone. Europe includes Belgium, France,
Germany, Italy, Spain, Sweden, and the UK. North
America includes Canada and the USA
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iPTH target range of 60–240 pg/mL [35], which
was associated with most Japanese patients
achieving iPTH\600 pg/mL. Additionally, more
aggressive use of medications, including vita-
min D and cinacalcet, in Japan (available since
2008) may have been beneficial.
Although hyperphosphatemia resulting from
poor urinary excretion is to be expected as CKD
progresses [11], management remains challeng-
ing because of poor adherence to dietary phos-
phate restriction and oral phosphate binders
[36]. Often the pill burden increases as CKD
progresses [37], and dietary restrictions become
more stringent, resulting in worsening compli-
ance over time. Observational studies suggest
that hyperphosphatemia alone is associated with
an increased risk of all-cause and CV mortality in
patients undergoing hemodialysis [16, 20, 33],
which suggests that more effective control of
hyperphosphatemia might reduce mortality
rates. In our analysis, the proportion of patients
with hyperphosphatemia was highest in China,
perhaps reflecting relatively low use of effective
phosphate binders. This is consistent with a
cross-sectional study of patients receiving dialy-
sis in China, which reported that uncontrolled
hyperphosphatemia was common and possibly
related to a phosphorus-rich diet, lack of nutri-
tionist support at most dialysis centers, and
inadequate use of phosphate binders [38].
The proportions of DOPPS phase 5 patients
with hypercalcemia in China (possibly related to
predominant use of calcium-based phosphate
binders) and the UK poses an additional concern
because hypercalcemia has been significantly
associated with cardiac arrhythmias and the risk
of death, independent of phosphorus levels. Our
analysis warrants a call to action by highlighting
inconsistent practices and outcomes concerning
SHPT management. Our results are consistent
with prior reports demonstrating worsening con-
trol of SHPT over time. Specifically, iPTH levels
have steadily increased from 1996 to 2011 in
patients on long-term hemodialysis in Europe,
Australia, New Zealand, and North America [22],
pointing to the need for greater awareness and
better management of SHPT in patients with CKD
and ESRD. Because SHPT is an early and progres-
sive [12, 39] complication of CKD, timely diag-
nosis and treatment is critical.
By conducting clinical audits of their own
practices [40], nephrologists may discover ways
to improve their use of medications and testing,
thus resulting in improved disease control and
favorable outcomes. For example, a survey of
medical directors of dialysis centers in Saudi
Arabia [41] revealed opportunities to increase
understanding of SHPT management. A com-
mittee of nephrologists from the Middle East
subsequently reviewed the 2009 KDIGO guide-
lines for the management of CKD-MBD [14] to
formulate practical, standardized regional rec-
ommendations [1]. Encouragingly, an analysis
of the management of patients undergoing
hemodialysis in Saudi Arabia from 2011 to 2013
found trends over time for better utilization of
drugs and improvement in laboratory parame-
ters [42]. Similarly, the Chinese guidance for
CKD-MBD management from 2013 is scheduled
for update in 2019 with the inclusion of more
data specific to China. In Russia, a group of
experts prepared national guidelines for the
treatment of CKD-MBD based on international
recommendations [43].
Individual country and center practices
described in this study may be translated for use
elsewhere. Although the data from this analysis
are retrospective and associative, there may be
opportunities for implementation of best prac-
tices to improve clinical outcomes. In Japan,
ambitious targets for iPTH were associated with
success in controlling levels of that hormone, a
strategy that could be applied to other parame-
ters and in other countries. Importantly,
stable maintenance of iPTH at B 600 pg/mL has
been associated with a lower rate of mortality in
patients undergoing hemodialysis [44]. Hyper-
phosphatemia was least common in France and
most common in China; although multiple fac-
tors could lead to hyperphosphatemia, the use of
non-calcium-based phosphate binders may be a
contributing factor to success. This has also been
demonstrated in previous analyses, in which
patients undergoing hemodialysis who were
receiving calcium-based phosphate binders had
decreased risk of mortality after initiating treat-
ment with sevelamer [45].
A limitation of this analysis is that PTH levels
were not measured in a centralized laboratory,
and PTH levels were not normalized to account
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for the differences in iPTH assays used globally
and between local hospitals in the same coun-
try. Furthermore, the variability in a country’s
public spending on health per capita may have
influenced the type of guidelines in local use,
thereby affecting the availability of resources,
management practices, and laboratory parame-
ters. Variability within a country is affected by
the sample size, which was not uniform. An
additional caveat is that, because of the design
of this analysis, patient outcomes were not
assessed, thus restricting conclusions about
whether the results for laboratory measures had
clinically meaningful implications. Nonethe-
less, given the known complications associated
with suboptimal management of SHPT, the
findings of this work are expected be relevant to
outcomes.
In summary, the management of SHPT is
complex, and effective management is important
because of the morbidity and mortality associated
with SHPT in patients with CKD stage 5. The dif-
ferences among countries observed in this analysis
suggest that aspects of the management of SHPT
are not universally accepted. The clearest single
factor associated with positive laboratory out-
comes in this study was lower target levels of iPTH,
which had beneficial effects on control of serum
phosphorus and calcium. Other gains can be made
by more intense use of vitamin D and cinacalcet
and more effective use of phosphate binders.
However, differences in available resources
between countries may limit the extent to which
management may be adjusted. In conclusion,
within the constraints of their individual situation,
dialysis centers have an opportunity to achieve
good patient outcomes by adjusting their targets to
achieve treatment goals with whatever means are
available to them.
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